Jenburkt Pharma

{
  "main_header": {
    "sid": 134395,
    "name": "Jenburkt Pharma",
    "stock_name": "Jenburkt Pharma",
    "full_name": "Jenburkt Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/jenburkt-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,007.25",
    "chg": 1.1,
    "chgp": "0.11%",
    "dir": 1,
    "prev_price": "1,006.15",
    "mcapval": "455.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524731,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE354A01013",
    "curr_date": "Mar 20",
    "curr_time": "",
    "bse_nse_vol": "2.27 k",
    "exc_status": "Active",
    "traded_date": "Mar 20, 2026",
    "traded_date_str": "2026 03 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jenburkt-pharma-134395-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3882643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JenburktPharmac_mojoScore_3882643.png",
        "date": "2026-03-10 10:10:02",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 10 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. Stock Falls to 52-Week Low of Rs.944",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-stock-falls-to-52-week-low-of-rs944-3869906",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JenburktPharmac_priceRelatedfactors_3869906.png",
        "date": "2026-03-04 12:40:03",
        "description": "Jenburkt Pharmaceuticals Ltd. touched a new 52-week low of Rs.944 today, marking a significant price level for the stock amid a mixed market environment. Despite outperforming its sector by 1.72% during the trading session, the stock declined by 5.41% intraday, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3857850",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/JenburktPharmac_mojoScore_3857850.png",
        "date": "2026-02-26 10:10:03",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3840920",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/JenburktPharmac_mojoScore_3840920.png",
        "date": "2026-02-15 10:10:19",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Jenburkt Pharmaceuticals Declines 0.89%: Valuation and Profit Concerns Shape Weekly Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-declines-089-valuation-and-profit-concerns-shape-weekly-trend-3827534",
        "imagepath": "",
        "date": "2026-02-08 16:02:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Feb:</strong> Stock opens at Rs.1,034.35, down 3.64% amid broader market weakness</p>\n                    <p><strong>3 Feb:</strong> Q3 FY26 results reveal sharp profit decline; stock surges 6.78%</p>\n                    <p><strong>4 Feb:</strong> Downgrade to Sell rating and valuation shift to expensive; stock falls 4.30%</p>\n                    <p><strong>5-6 Feb:</strong> Modest gains on low volumes; week closes at Rs.1,063.85 (-0.89%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,034.35</div></div>\n                    <div class=\"stat-item\"><di..."
      },
      {
        "title": "Are Jenburkt Pharmaceuticals Ltd. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-jenburkt-pharmaceuticals-ltd-latest-results-good-or-bad-3820976",
        "imagepath": "",
        "date": "2026-02-04 19:16:28",
        "description": "Jenburkt Pharmaceuticals Ltd. has reported its financial results for the quarter ended December 2025, revealing significant operational challenges. The company experienced a net profit of ₹5.93 crores, which reflects a notable decline of 41.63% compared to the previous quarter. This decline in profitability occurred despite a year-on-year revenue growth of 16.62%, indicating that the company is facing severe operational pressures.\n\nThe net sales for the quarter amounted to ₹43.02 crores, which represents a sequential decrease of 5.58% from ₹45.56 crores in the prior quarter. This drop in sales, coupled with a sharp contraction in operating profit—falling to ₹7.42 crores from ₹13.10 crores—highlights a worrying trend in operational efficiency. The operating margin has also compressed significantly to 17.25%, down 1,150 basis points from the previous quarter, marking the lowest level in recent history.\n\nFurth..."
      },
      {
        "title": "Jenburkt Pharmaceuticals Downgraded to Sell Amid Valuation and Technical Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-downgraded-to-sell-amid-valuation-and-technical-concerns-3819694",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/JenburktPharmac_mojoScore_3819694.png",
        "date": "2026-02-04 08:03:32",
        "description": "Jenburkt Pharmaceuticals Ltd., a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 3 February 2026. This shift reflects a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. The downgrade comes amid rising valuation concerns, subdued financial performance, and a cautious technical outlook, despite some long-term growth strengths."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd: Valuation Shift Signals Expensive Territory Amid Mixed Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-valuation-shift-signals-expensive-territory-amid-mixed-returns-3819433",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/JenburktPharmac_valuationdot_3819433.png",
        "date": "2026-02-04 08:00:10",
        "description": "Jenburkt Pharmaceuticals Ltd. has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating, prompting a downgrade in its Mojo Grade from Hold to Sell. This change reflects evolving market perceptions amid mixed financial metrics and relative performance against peers and benchmarks."
      },
      {
        "title": "Jenburkt Pharmaceuticals Q3 FY26: Sharp Profit Decline Amid Margin Pressures Raises Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/jenburkt-pharmaceuticals-q3-fy26-sharp-profit-decline-amid-margin-pressures-raises-concerns-3819014",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/JenburktPharmac_quaterlyResult_3819014.png",
        "date": "2026-02-03 19:30:36",
        "description": "Jenburkt Pharmaceuticals Ltd., a Mumbai-based speciality pharmaceutical formulations manufacturer, reported a concerning quarter-on-quarter decline in profitability for Q3 FY26, with net profit falling 41.63% to ₹5.93 crores from ₹10.16 crores in the previous quarter. Despite posting year-on-year revenue growth of 16.62%, the company's operating margins contracted sharply to 17.25% from 28.75% in Q2 FY26, marking the lowest quarterly operating margin in recent periods. The stock, with a market capitalisation of ₹458 crores, closed at ₹1,105.00 on February 3, 2026, gaining 6.83% on the day but remains down 13.39% over the past three months."
      }
    ],
    "total": 494,
    "sid": "134395",
    "stock_news_url": "https://www.marketsmojo.com/news/jenburkt-pharmaceuticals-134395"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "04-Feb-2026",
      "details": "Newspaper Publication for Unaudited statndalone financial Statement for the quarter and nine months ended on 31st Decemeber 2025.",
      "source": "BSE"
    },
    {
      "caption": "Standalone Unaudited Financial Results For The Quarter And Nine Months Ended On 31St December 2025.",
      "datetime": "03-Feb-2026",
      "details": "Standalone Unaudited financial results for the quarter and nine months ended on 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held Today On 03Rd February 2026.",
      "datetime": "03-Feb-2026",
      "details": "Outcome of the Board Meeting held today on 03rd February 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jenburkt Pharmaceuticals Ltd. has declared <strong>180%</strong> dividend, ex-date: 11 Jul 25",
          "dt": "2025-07-11",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-03-10 10:10:02

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 10 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Jenburkt Pharmaceuticals Ltd. Stock Falls to 52-Week Low of Rs.944

2026-03-04 12:40:03

Jenburkt Pharmaceuticals Ltd. touched a new 52-week low of Rs.944 today, marking a significant price level for the stock amid a mixed market environment. Despite outperforming its sector by 1.72% during the trading session, the stock declined by 5.41% intraday, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Read full news article

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-02-26 10:10:03

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-02-15 10:10:19

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Jenburkt Pharmaceuticals Declines 0.89%: Valuation and Profit Concerns Shape Weekly Trend

2026-02-08 16:02:08

Key Events This Week

2 Feb: Stock opens at Rs.1,034.35, down 3.64% amid broader market weakness

3 Feb: Q3 FY26 results reveal sharp profit decline; stock surges 6.78%

4 Feb: Downgrade to Sell rating and valuation shift to expensive; stock falls 4.30%

5-6 Feb: Modest gains on low volumes; week closes at Rs.1,063.85 (-0.89%)

Week Open

Rs.1,034.35

Read full news article

Are Jenburkt Pharmaceuticals Ltd. latest results good or bad?

2026-02-04 19:16:28

Jenburkt Pharmaceuticals Ltd. has reported its financial results for the quarter ended December 2025, revealing significant operational challenges. The company experienced a net profit of ₹5.93 crores, which reflects a notable decline of 41.63% compared to the previous quarter. This decline in profitability occurred despite a year-on-year revenue growth of 16.62%, indicating that the company is facing severe operational pressures. The net sales for the quarter amounted to ₹43.02 crores, which represents a sequential decrease of 5.58% from ₹45.56 crores in the prior quarter. This drop in sales, coupled with a sharp contraction in operating profit—falling to ₹7.42 crores from ₹13.10 crores—highlights a worrying trend in operational efficiency. The operating margin has also compressed significantly to 17.25%, down 1,150 basis points from the previous quarter, marking the lowest level in recent history. Furth...

Read full news article

Jenburkt Pharmaceuticals Downgraded to Sell Amid Valuation and Technical Concerns

2026-02-04 08:03:32

Jenburkt Pharmaceuticals Ltd., a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 3 February 2026. This shift reflects a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. The downgrade comes amid rising valuation concerns, subdued financial performance, and a cautious technical outlook, despite some long-term growth strengths.

Read full news article

Jenburkt Pharmaceuticals Ltd: Valuation Shift Signals Expensive Territory Amid Mixed Returns

2026-02-04 08:00:10

Jenburkt Pharmaceuticals Ltd. has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating, prompting a downgrade in its Mojo Grade from Hold to Sell. This change reflects evolving market perceptions amid mixed financial metrics and relative performance against peers and benchmarks.

Read full news article

Jenburkt Pharmaceuticals Q3 FY26: Sharp Profit Decline Amid Margin Pressures Raises Concerns

2026-02-03 19:30:36

Jenburkt Pharmaceuticals Ltd., a Mumbai-based speciality pharmaceutical formulations manufacturer, reported a concerning quarter-on-quarter decline in profitability for Q3 FY26, with net profit falling 41.63% to ₹5.93 crores from ₹10.16 crores in the previous quarter. Despite posting year-on-year revenue growth of 16.62%, the company's operating margins contracted sharply to 17.25% from 28.75% in Q2 FY26, marking the lowest quarterly operating margin in recent periods. The stock, with a market capitalisation of ₹458 crores, closed at ₹1,105.00 on February 3, 2026, gaining 6.83% on the day but remains down 13.39% over the past three months.

Read full news article

View All News